Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Nine of the world’s top 10 pharmaceutical manufacturers now use Redi Health to modernize patient support, according to a sponsored report published on July 13, 2026. The shift reflects demand for faster, more personalized patient experiences. However, it also places
Spero Therapeutics is shifting from antibiotics to immune and inflammatory diseases through a licensing agreement with Innovent Biologics worth up to $1.1 billion. The company will develop SP001, a CD40L antibody, outside China. At the same time, Spero secured $105
Emerging Biotech Hubs across North America, Europe, and Asia are attracting new pharmaceutical investments, research facilities, and global talent in 2026. While this expansion reflects strong industry growth, it also introduces new GMP Compliance challenges, validation demands, and Quality Systems
The U.S. Food and Drug Administration (FDA) is facing growing attention over how it evaluates Rare Disease Therapies in 2026. Discussions around FDA Advisory Committees (AdComms) and patient-focused decision-making highlight a broader regulatory transformation that may reshape how pharmaceutical companies
Leadership experts in the healthcare sector have warned that organizational strategies often become vulnerable during executive transitions when they rely on individual leaders instead of institutional governance. Although the discussion originated from healthcare leadership, its implications extend directly to Pharmaceutical
The U.S. Food and Drug Administration (FDA) has approved the subcutaneous formulation of isatuximab-irfc (Sarclisa Escena) for three multiple myeloma treatment regimens, expanding an anti-CD38 therapy that was previously available only as an intravenous infusion. While the approval offers patients
The FDA has paused the public release of new Complete Response Letters (CRLs) while reviewing a citizen petition that challenges the legal basis of the disclosure program. The decision temporarily interrupts one of the agency’s most significant transparency initiatives and
Artificial intelligence has taken another step from research into regulated drug development. Chinese biotech MindRank has secured $52 million in Series B funding to advance its AI-powered drug discovery platform and accelerate the clinical development of its oral GLP-1 receptor
The U.S. Department of Health and Human Services (HHS) has introduced Operation Trialblazer, a multi-agency initiative designed to accelerate early-stage drug development and modernize clinical research across the United States. Working alongside the FDA and the National Institutes of Health
The U.S. Food and Drug Administration (FDA) has temporarily paused the public release of Complete Response Letters (CRLs). The agency made the decision after an unnamed pharmaceutical company challenged the policy over confidentiality concerns. The move temporarily suspends one of